 DARTMOUTH, Nova Scotia--BUSINESS WIRE--- IMV--IMV Inc. the Company or IMV NASDAQ: IMV; TSX: IMV, a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced the appointment of Mr. Kyle Kuvalanka to its Board of Directors effective April 1, 2021. Mr. Kuvalanka brings over 20 years of experience as a senior leader in the biopharmaceutical industry with a successful track record in forming and negotiating strategic collaborations, leading financings, 